{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-349022","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2021-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.774547+00:00","generated_at":"2026-06-28T03:29:25.785838+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Karyopharm director Mikael Dolsten resigns; Peter Honig elected to board","bullets":["Director Mikael Dolsten resigned effective Dec 2, 2021, citing competing professional demands, no disagreement.","Peter Honig elected independent director effective Dec 3, 2021, filling a vacancy, Class III term until 2022 annual meeting.","Honig appointed to Commercialization and Portfolio Committee; awarded option for 47,800 shares at $6.72, vesting over 3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-349022","json":"https://secwatch.observer/filing/0001193125-21-349022.json","markdown":"https://secwatch.observer/filing/0001193125-21-349022.md","text":"https://secwatch.observer/filing/0001193125-21-349022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/d203828d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T03:29:25.785838+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ed11eaaf3","claim":"Mikael Dolsten resigned as Director at Karyopharm Therapeutics Inc..","evidence_excerpt":"On December 2, 2021, Mikael Dolsten, MD, PhD, notified Karyopharm Therapeutics Inc. (the “Company”) of his resignation from the Board of Directors (the “Board”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"d3255a0f11","claim":"Peter Honig was elected as Director at Karyopharm Therapeutics Inc..","evidence_excerpt":"On December 3, 2021, the Board, upon the recommendation of the Nominating, Corporate Governance & Compliance Committee of the Board, elected Peter K Honig, M.D., MPH, as an independent director of the Company to fill a vacancy on the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312521349022/0001193125-21-349022-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}